MEK Inhibition Enhances Presentation of Targetable MHC-I Tumor Antigens in Mutant Melanomas

Researchers leveraged the tunable abundance of MEK inhibition-modulated antigens by targeting four epitopes with peptide major histocompatibility molecules (pMHC)-specific T cell engagers and antibody drug conjugates, enhancing cell killing in melanoma cells following MEK inhibition.